Navigation Links
RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
Date:1/24/2011

ROCKVILLE, Md., Jan. 24, 2011 /PRNewswire/ -- RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

The RRD and TRND partnership will focus on two rare disease drug development projects: Hereditary Inclusion Body Myopathy (HIBM), a rare adult-onset neuromuscular disorder and Niemann Pick type C1 Disease (NPC1), a rare neurodegenerative genetic disease.  

"We look forward to combining the product development strengths of RRD with the resources of the NIH TRND program to develop important new treatments for these rare diseases," said Charles (Chuck) Finn, Ph.D., President, CEO, and Co-Founder of RRD International.

As a new congressionally mandated program, TRND is designed to advance preclinical and early clinical development of new drugs for rare and neglected diseases. The program also drives forward adoption of new technologies and treatment paradigms which improve product development efficiency for these diseases.  TRND has formed numerous collaborations with researchers from academia and industry to work on specific rare or neglected diseases.  

"TRND has established partnerships with companies and researchers to identify the most promising molecules that may result in new treatments for rare and neglected diseases," said Christopher P. Austin, M.D., director of the NIH TRND effort. "It is important to note that drug development is not a trivial process and the failure rate for any molecule or compound is high."

The program aims to speed development of new drugs that might otherwise be ignored by industry because they are too early in the development process where the failure rates are high or would not be sufficiently profitable. To make a potential compound attractive to private partners in order to get a treatment to patients, TRND advances a potential compound through the drug development process to the point where it can be tested in people. TRND provides all aspects of preclinical development needed to turn promising compounds into potential medicines ready for clinical evaluation.

"This partnership is another validation of our development philosophy and the success we've achieved with other products," said Scott Tarrant, Chief Business Officer at RRD International. "Work on these rare diseases will demonstrate the flexibility of our asset-centric model and how RRD efficiently drives development while mitigating cost and risk factors which, historically, have served as barriers to new therapies for rare and neglected diseases."

The TRND program will collaborate with academic organizations, foundations, biotechs, and pharmaceutical companies to develop clinical candidate drugs that can be adopted by biopharma for completion of clinical development and FDA approval.  In addition to individual drug development projects, TRND is developing technologies and paradigms to reduce the very high risks and cost of drug development. The ultimate goal is to "de-risk" rare and neglected disease drug development by accomplishing lead optimization through an FDA Investigational New Drug (IND) application and, when needed, proof-of-concept in human studies.

About RRD International

Founded in 2002, RRD is a strategy-driven product development company.  The Company's development model enables rapid proof-of-concept for biotech and pharmaceutical clients to accelerate value inflection points; reduce costs; and mitigate development as well as execution risk.  RRD offers two distinct types of client engagements:  TacDev® and DevCo®.  The TacDev® model adds development bandwidth and expertise for defined products in companies with minimal infrastructure.  The DevCo® model creates external product development companies where investment is in asset optimization rather than traditional infrastructure.  For more information visit www.rrdintl.com.  RRD International: Accelerating the Right Development; Creating Lasting Value.

About TRND

The National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program, http://trnd.nih.gov is a congressionally mandated program to encourage and speed the development of new drugs for rare and neglected diseases.  This unique program creates a drug development pipeline within the NIH and is specifically intended to stimulate research collaborations with academic scientists, non-profit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses.  The TRND program provides an opportunity to partner with, and gain access to, drug development scientific capabilities, expertise, and resources in a collaborative environment with the goal of moving promising therapeutics into clinical testing.


'/>"/>
SOURCE RRD International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
3. PMC BioTec Selected as a GoingGreen Silicon Valley 100 Winner
4. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
5. Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility
6. Ion Torrent Selected as World Economic Forum Technology Pioneer
7. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
8. Genedata Phylosopher Selected for ERA-NET sncRNA Project
9. NeoStem Selected to Present at American Society for Apheresis
10. DNA Genoteks Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project
11. OrthoAccel Technologies, Inc. Selected to Pitch at the 2010 WBTshowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
(Date:6/22/2016)... --  StockNewsNow.com , The Official MicroCap News Source™, today ... Pourhassan , President & CEO of CytoDyn Inc. (OTCQB: ... and potential commercialization of humanized monoclonal antibodies for the ... company,s website (see here: www.CytoDyn.com ). The video ... 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... ... , ... New light-based technologies that facilitate a “look inside” the human body ... compact, wearable devices for point-of-care diagnostics as well as powerful new systems that provide ... visionary future directions are detailed in a new open-access article by Antonio Pifferi and ...
(Date:6/22/2016)... and ALBANY, N.Y. , ... (Teewinot) and Albany Molecular Research, Inc. (NASDAQ: ... licensed Teewinot,s technology to produce and sell the ... The CBCA analytical standard is manufactured using Teewinot,s ... expression of cannabinoid biosynthetic genes in microorganisms for ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):